Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follo
about
Radiation Therapy after Radical Prostatectomy: Implications for CliniciansSaudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancerIntegrating Geriatric Assessment into Decision-Making after Prostatectomy: Adjuvant Radiotherapy, Salvage Radiotherapy, or None?Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer after permanent prostate brachytherapy with a review of the literatureFifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancerEnzalutamide in metastatic prostate cancer before chemotherapy.The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate-a long-term follow-up comparison and quality of life analysis.Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up studySolitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report.Survival following primary androgen deprivation therapy for localized intermediate- or high-risk prostate cancer: comparison with the life expectancy of the age-matched normal population.Adverse effects of androgen-deprivation therapy in prostate cancer and their management.Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance.Systematic review: does endocrine therapy prolong survival in patients with prostate cancer?Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management.Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.Second salvage treatment for local recurrence of prostate cancer using high-dose-rate brachytherapy: a case report.Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer.Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy.Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer.Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease.Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients.
P2860
Q26744531-6750B1C0-6BE3-4FD3-A077-5F1F6797C45BQ26747782-B61819EF-04C7-41B2-8DBA-7DD89A3E0992Q26777128-245DFBA9-18CD-4A97-9A70-8261D6EA26EEQ28828469-B5F30E3E-5041-4148-A4EF-9DC5F7743CB9Q33877542-533FCD25-B825-47E0-8F02-8B8C3B611E4CQ34422206-72A53652-7802-47D3-9CBC-94D16EA59BD1Q34531624-DD58B78E-561B-40B2-B91F-63AFC44AEA49Q35470434-FE26323F-578C-4161-9E59-DF60D3203868Q36502875-0E9E6753-75DA-42A6-B400-4ED85105E511Q38208193-3D3C66E9-F63B-440A-90CE-9223E7109341Q38261253-82272CAC-EC0A-4538-BC7B-A1A4CE0E6247Q38537545-BB323583-38A1-409A-B04C-6A068E44A4ACQ38747059-F989A21E-0327-4F3A-82C3-3B30DC665CA0Q38779039-6771B520-2E53-482F-A9E7-A8B39AF5E55CQ38803264-14FC7DF8-EABC-4D2B-A8DE-B1E4F6815049Q41115792-74D9A9C6-84F1-471D-BC0D-A3086C14571AQ43427594-7F8855C7-F902-42C0-82C7-7418206F9F0BQ49084411-13554D82-2F7C-4C7A-8333-1C73152DE55AQ49096071-06336ABA-2030-4862-ADDC-9B512D5413B7Q53098000-FC5EDF99-D31E-4FD3-A3AC-FCD015D28289Q53660770-D33FE4D4-5429-484E-8B10-0FBEFCFE72A5
P2860
Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follo
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Differences in time to disease ...... l 30891 with 12 years of follo
@en
Differences in time to disease ...... l 30891 with 12 years of follo
@nl
type
label
Differences in time to disease ...... l 30891 with 12 years of follo
@en
Differences in time to disease ...... l 30891 with 12 years of follo
@nl
prefLabel
Differences in time to disease ...... l 30891 with 12 years of follo
@en
Differences in time to disease ...... l 30891 with 12 years of follo
@nl
P2093
P1433
P1476
Differences in time to disease ...... l 30891 with 12 years of follo
@en
P2093
EORTC Genitourinary Cancer Group
Florian Wimpissinger
Hartmut Knönagel
Jacques Casselman
Laurence Collette
Peter Whelan
Santiago Isorna
Subramanian K Sundaram
Theo M de Reijke
Urs E Studer
P304
P356
10.1016/J.EURURO.2013.07.024
P407
P577
2013-07-24T00:00:00Z